Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity (2012 - 2026)

Enanta Pharmaceuticals' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $314.7 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 2.57% year-over-year to $314.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 15.28% YoY) and the FY2025 annual result came in at $280.7 million, down 25.47% from the prior year.
• Liabilities and Shareholders Equity was $314.7 million for Q1 2026 at Enanta Pharmaceuticals, down from $329.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $495.2 million in Q2 2023 and bottomed at $280.7 million in Q3 2025.
• A 5-year average of $371.4 million and a median of $375.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity rose 28.54% — and 2025, when it dropped 25.47%.
• Enanta Pharmaceuticals' Liabilities and Shareholders Equity stood at $347.5 million in 2022, then grew by 23.3% to $428.5 million in 2023, then slipped by 18.64% to $348.6 million in 2024, then dropped by 5.49% to $329.5 million in 2025, then decreased by 4.49% to $314.7 million in 2026.
• Business Quant data shows ENTA's Liabilities and Shareholders Equity at $314.7 million in Q1 2026, $329.5 million in Q4 2025, and $280.7 million in Q3 2025.